RESUMEN
BACKGROUND: We aimed to investigate the relationship between blood groups and pancreatic cancer in a Turkish population in Western Blacksea region. METHODS: This is a retrospective study. Zonguldak Karaelmas University outpatient oncology clinic records were screened for the period between 2004 and 2011. RESULTS: The median age of patients were 56 (± 16) and 132 of 633 study population had pancreatic cancer. Pancreatic cancer patients had significantly higher rates of blood group A compared to controls (OR 1.8, 95%CI, p 0.005). Rates of blood group AB was significantly lower than the control group (OR 0.37, 95% CI, p 0.04). The median survival (IR) time in subjects having the blood groups A, B, AB and O were 7.0 (1-28), 7.0 (2-38), 10 (2-36) and 9.0 (2-48) months respectively; the blood group 0 had significantly higher overall survival (OS) compared to the non-0 groups (p 0.04). CONCLUSIONS: Pancreatic cancer patients had more common blood group A in our population. Moreover, blood group AB appeared to be a protective factor against pancreatic cancer in our population. Blood group 0 had a significantly longer survival compared to non-0, regardless of prognostic factors.
Asunto(s)
Sistema del Grupo Sanguíneo ABO , Neoplasias Pancreáticas/etiología , Neoplasias Pancreáticas/mortalidad , Estudios de Casos y Controles , Susceptibilidad a Enfermedades , Femenino , Humanos , Masculino , Persona de Mediana Edad , Neoplasias Pancreáticas/epidemiología , Neoplasias Pancreáticas/prevención & control , Pronóstico , Estudios Retrospectivos , Medición de Riesgo , Encuestas y Cuestionarios , Tasa de Supervivencia , Turquía/epidemiologíaRESUMEN
PURPOSE: Radiotherapy is the most frequently used and cheapest treatment both for curative and palliative purposes in HNSCC. Despite advances in technology and intensive treatments with radiation, only half of the patients are cured. New therapeutic approaches focusing on the molecular mechanism that mediate tumour cell growth or cell death in combination with radiotherapy have been suggested. The effects of radiation, antibody to EGFR and Docetaxel as single treatment or in combinations on HNSCC cells were investigated. METHODS: The established HNSCC cells with mutant (mt) P53 and over-expressed normal EGFR was used as the in vitro model. Gene expression profile, cell cycle progression and cell death were used as the indication of treatment outcome. RESULTS: With c-DNA microarray of well-characterised functional genes, massive changes in the genes expression of HNSCC were detected. The alterations of gene expression profiles do not have any correlation neither on tumour cell growth nor cell death. HNSCC cells with mt P53 and over-expressed normal EGFR did not response to radiation, anti-EGFR monoclonal antibody and their combination therapy. Effective treatment could be obtained from single therapy with Docetaxel. No additive effects on cell cycle arrest or cell death were seen in the combination of Docetaxel to anti-EGFR antibody, radiation or anti-EGFR antibody + radiation. CONCLUSIONS: The c-DNA microarray analysis does not indicate any specific target or treatment effects of HNSCC with mt P53 and over-expressed normal EGFR. Single therapy, target at microtubules might be the most suitable treatment modulation in this tumour type.
Asunto(s)
Anticuerpos Monoclonales/uso terapéutico , Carcinoma de Células Escamosas/tratamiento farmacológico , Carcinoma de Células Escamosas/radioterapia , Receptores ErbB/genética , Receptores ErbB/inmunología , Regulación de la Expresión Génica , Neoplasias de Cabeza y Cuello/tratamiento farmacológico , Neoplasias de Cabeza y Cuello/radioterapia , Taxoides/uso terapéutico , Proteína p53 Supresora de Tumor/genética , Carcinoma de Células Escamosas/genética , Carcinoma de Células Escamosas/inmunología , Ciclo Celular/efectos de los fármacos , Ciclo Celular/efectos de la radiación , Muerte Celular/efectos de los fármacos , Muerte Celular/efectos de la radiación , Línea Celular Tumoral , Terapia Combinada , ADN Complementario/genética , Docetaxel , Perfilación de la Expresión Génica , Neoplasias de Cabeza y Cuello/genética , Neoplasias de Cabeza y Cuello/inmunología , Humanos , Análisis de Secuencia por Matrices de Oligonucleótidos , Proteína p53 Supresora de Tumor/inmunologíaRESUMEN
INTRODUCTION: Recent research has suggested that serum tumor markers can give valuable prognostic information in gastric cancer. In this study, we examined the relationship between preoperative serum carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 19-9, CA 72-4, and alfa fetoprotein (AFP) levels on clinicopathologic significance in gastric cancer patients. METHODS: Preoperative plasma levels of CEA, CA 19-9, CA 72-4, and AFP were retrospectively examined in 95 patients who underwent surgical resection for gastric cancer, and the prognostic value of the tumour markers were estimated. RESULTS: The percentage of CA 19-9, CA 72-4, CEA, and AFP-positive cases were 41%, 32.6%, 24.2%, and 8.4%, respectively. CEA was more frequently positive in the patients with liver metastases (P=0.02). CA 19-9 was more frequently positive in patients with lymph node (P=0.005), peritoneal (P=0.01), and serosal (P=0.03) involvement. CA 72-4 was more frequently positive in patients with lymph node (P=0.01), peritoneal (P=0.03), and liver (P=0.01) involvement. Low 3-year cumulative survival was associated significantly with elevated serum levels of CEA (P=0.001), CA 19-9 (P=0.001), CA 72-4 (P=0.001), and AFP (P=0.01). In multivariate analysis, age, tumor stage, and CA 72-4 were the only independent prognostic factors. Being positive for CA 72-4 was associated with a 3.8-fold higher risk of death (95% confidence intervals: 1.3, 10.9). CONCLUSION: Our results suggest that high preoperative serum levels of CA 72-4 in gastric cancer patients are associated with a higher risk of death due to gastric cancer.
Asunto(s)
Antígenos de Carbohidratos Asociados a Tumores/sangre , Antígeno Carcinoembrionario/sangre , Neoplasias Gástricas/diagnóstico , alfa-Fetoproteínas/análisis , Adulto , Anciano , Biomarcadores , Femenino , Humanos , Masculino , Persona de Mediana Edad , Cuidados Preoperatorios , Pronóstico , Estudios Retrospectivos , Neoplasias Gástricas/cirugíaRESUMEN
INTRODUCTION: Primary ovarian choriocarcinoma arising presumably from a germ cell is extremely rare. Besides arising gestationally or nongestationally, it may be pure or mixed with other germ cell tumors like immature teratoma, dysgerminoma, polyembryoma. CASE REPORT AND DISCUSSION: We present a case of a 22-year-old woman diagnosed with pure nongestational choriocarcinoma of the ovary with a review of the literature and discussion of its origin.
Asunto(s)
Coriocarcinoma no Gestacional/cirugía , Neoplasias Ováricas/cirugía , Adulto , Coriocarcinoma no Gestacional/patología , Femenino , Procedimientos Quirúrgicos Ginecológicos , Humanos , Estadificación de Neoplasias , Neoplasias Ováricas/patologíaRESUMEN
BACKGROUND: Markers of an acute phase reaction, such as C-reactive protein (CRP) or tumor necrosis factor-alpha (TNF-alpha) and interleukin (IL)-6, are predictive for cardiovascular morbidity and mortality in normal subjects and in chronic renal failure patients. In this study, we aimed to investigate serum TNF-alpha, IL-6, IL-10 and CRP levels in continuous ambulatory peritoneal dialysis (CAPD) and hemodialysis (HD) patients. MATERIALS AND METHODS: Serum levels of TNF-alpha, IL-6, IL-10 and CRP levels were measured in 30 patients who were just diagnosed with end-stage renal failure and treated, with 16 CAPD (nine female, seven male) and 14 HD (eight female, six male) patients, before CAPD or HD treatment and after 3 months from the beginning of CAPD or HD in patients with no clinical signs of infection. The control groups were 20 healthy persons of similar age and sex. Serum levels of TNF-alpha, IL-6, IL-10 and CRP were measured by enzyme-linked immunosorbent assay in stable CAPD and HD patients and in healthy persons. RESULTS: The mean serum levels of TNF-alpha, IL-6, IL-10 and CRP showed no significant differences between the CAPD and HD patients for the beginning values and the third month of treatment. However, serum TNF-alpha, IL-6, IL-10 and CRP levels were higher than the control group in the CAPD and HD patients regarding the beginning values and the third month of treatment (p < 0.001). CONCLUSIONS: CAPD and HD of the renal replacement therapy have no effects on serum CRP and cytokines.
Asunto(s)
Interleucina-10/sangre , Interleucina-6/sangre , Fallo Renal Crónico/terapia , Diálisis Peritoneal Ambulatoria Continua , Diálisis Renal , Factor de Necrosis Tumoral alfa/metabolismo , Proteína C-Reactiva/metabolismo , Femenino , Humanos , Fallo Renal Crónico/sangre , Fallo Renal Crónico/inmunología , Masculino , Valores de ReferenciaRESUMEN
The present study was carried out to evaluate the effects of 1alpha,25-dihydroxyvitamin D3 (VD) on chromosomal aberrations induced by doxorubicin (DXR). Wistar rats were divided into eight experimental groups of five animals each. Control group animals were treated with i.p. distilled water. The animals in three VD groups were given only VD for 4, 6 or 8 weeks. In the DXR groups the animals were given only DXR. In the combination groups VD doses were given for 4, 6 or 8 weeks for each group and DXR was injected 24 h before sacrificing the rats. DXR (50 mg/100 g b.w.) was injected intraperitoneally and VD by gavage 3 microg/kg/day twice weekly. Animals treated with both VD and DXR showed a low frequency of chromosomal aberrations and abnormal metaphases when compared with animals treated with DXR alone (p < 0.0001). The numbers of both chromosomal aberrations and abnormal metaphases were similar in weeks 6 and 8 (p > 0.05) and lower than those in week 4 for the VD groups (p < 0.0001). Under the present experimental conditions, the efficiency of VD in protecting cells against DXR-induced chromosome damage was found to be dose dependent. The protective effects of VD on chromosome aberrations induced by DXR are discussed in the light of literature data.
Asunto(s)
Células de la Médula Ósea/efectos de los fármacos , Calcitriol/farmacología , Aberraciones Cromosómicas/efectos de los fármacos , Doxorrubicina/efectos adversos , Animales , Calcitriol/administración & dosificación , Relación Dosis-Respuesta a Droga , Doxorrubicina/administración & dosificación , Metafase/efectos de los fármacos , Ratas , Ratas WistarRESUMEN
The present study was carried out to evaluate the role of vitamin A (VA) on the induction of chromosomal aberrations (CA) in rat bone marrow cells and to investigate its modulating effect on chromosomal damage induced by doxorubicin (DXR). Wistar rats were treated with VA (7.5, 15 and 30 microg/kg body wt) once a day for 2 days by gavage before injecting DXR (90 mg/kg body wt). Rats in the control group were treated with corresponding doses of water and olive oil. Animals treated with the medium dose of VA (15 microg/kg body wt) plus single dose of DXR presented a statistically significant reduction in total number of CA and in number of abnormal metaphases (P < 0.05). However, when compared with control and DXR groups, the low and high VA doses (7.5 and 30 microg/kg body wt) were found to be less efficient than the medium dose VA (15 microg/kg body wt) in terms of parameters analyzed. Furthermore, the high dose of VA group (30 microg/kg body wt) was found to be clastogenic (P < 0.05). This study concludes that the protective effect of VA against chromosome damage is dose dependent.
Asunto(s)
Antibióticos Antineoplásicos/farmacología , Células de la Médula Ósea/efectos de los fármacos , Aberraciones Cromosómicas/inducido químicamente , Doxorrubicina/farmacología , Vitamina A/farmacología , Animales , Aberraciones Cromosómicas/efectos de los fármacos , RatasRESUMEN
The aim was to reassess the diagnostic value of tumour markers such as carcinoembryonic antigen (CEA), cancer antigen (CA) 15-3, CA 19-9 and CA 72-4 in the pleural fluid of various diseases, both in benign and malignant. Eighty-one patients (41 malignant and 40 benign pleural effusion) were included in this study. The effusion levels of CEA, CA 15-3, CA 19-9 and CA 72-4 were assayed with commercial enzyme immunoassays. CEA, CA 15-3, CA 19-9 and CA 72-4 mean pleural effusion fluid levels in malignant group were found to be significantly higher than that in benign group, but CA 19-9 mean pleural effusion fluid levels of malignant and benign group were similar. It was of interest to evaluate the prediction of the origin by pleural tumour markers. In pleurisies with a negative cytology, these assays are particularly useful when the clinical presentation cannot clearly exclude an underlying malignancy.
Asunto(s)
Antígenos de Neoplasias/análisis , Biomarcadores de Tumor/análisis , Neoplasias/diagnóstico , Derrame Pleural/diagnóstico , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Masculino , Persona de Mediana Edad , Neoplasias/inmunología , Valor Predictivo de las Pruebas , Estudios Prospectivos , Sensibilidad y EspecificidadRESUMEN
Continuous ambulatory peritoneal dialysis (CAPD) is widely used in the treatment of end stage renal failure patients. Delayed injury to the bowel is an uncommon complication of CAPD catheter. In this article, we presented a case of bowel perforation during catheter removal after the sixth month of peritoneal dialysis termination.
Asunto(s)
Catéteres de Permanencia/efectos adversos , Perforación Intestinal/etiología , Diálisis Peritoneal Ambulatoria Continua/efectos adversos , Adulto , Remoción de Dispositivos , Humanos , MasculinoRESUMEN
The records of the 324 patients with breast cancer; diagnosed and followed in two different University Hospital between years of January 1992 and January 2002 were reviewed retrospectively. The median age of the patients was 49.0+/-12.5 years, with the range of 18 and 90 years. The most frequently seen age interval of the patients was 40 and 49 years. The most frequently seen symptom and physical examination finding of the patients were breast mass. Breast cancer was diagnosed in 324 women, 173 in the left breast and 151 in the right breast. At the hospital admission percentages of the patients' disease stages were as follows: I (2.8%), IIA (30.0%), IIB (24.0%), IIIA (19.8%), IIIB (11.4) and IV (12.0%). The most frequently seen histopathological diagnosis was infiltrative ductal carcinoma (84.4%). Axillary lymph node metastasis was found in 61.7% of the patients. Primary therapeutic options and percentages were surgical therapy (78.5%), systemic chemotherapy (17.5%) and radiotherapy (4%). Systemic chemotherapy was given to 81.2% of the patients. From the files, estrogen receptor status was known in 311 and positive in 128 (41.2%) of them. Tamoxifen was given patients who had positive estrogen receptor. The five-year survival rate of the patients was calculated as 75.9%.
Asunto(s)
Neoplasias de la Mama/diagnóstico , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Neoplasias de la Mama/patología , Neoplasias de la Mama/terapia , Femenino , Humanos , Persona de Mediana Edad , Estudios RetrospectivosRESUMEN
This report describes a non-Hodgkin lyphoma case presenting with skeletal muscle and cutaneous involvement. A 75 year-old man was admitted to hospital with mass in the right upper extremity and skin lesions on the back of his trunk. Excisional mass biopsy was reported immunohistopthologically as large B-cell lymphoma. Primary extranodal lymphoma arising from skeletal muscle and concomitant skin infiltration of other body localization is not common. So this case was represented and relevant literature was reviewed.